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Therapeutic plasma exchange (TPE) has been used to re-
move immunoglobulin and other immunologically active
substances, such as complements or cytokines (Hughes et
al., 2007). TPE can thereby be used in many neurological
disorders where the main pathological substrate is autoim-
mune aetiology, such as Guillain-Barrè syndrome, Myasthe-
nia Gravis and others. However, the benefit of plasma ex-
change in CNS demyelinating diseases such as multiple
sclerosis (MS) and Neuromyelitis optica (NMO), is still de-
bated, mainly due to lack of randomised control trials.
Multiple sclerosis is a multifocal inflammatory disease of
the CNS, characterised by chronic inflammation, demy-
elination, axonal damage, and subsequent gliosis. Current
concepts of its pathogenesis assume that in genetically sus-
ceptible individuals, potentially self-reactive T cells are
activated in the immune system, home onto the CNS, and
may initiate tissue damage via release of inflammatory
cytokines, stimulation of B cells and macrophages, and acti-
vation of the complement system. Antibodies against my-
elin basic protein and myelin oligodendrocyte glycoprotein
have been detected in subgroups of patients with MS. These
antibodies may mediate injury by complement fixation or
linking with innate immune effector cells such as macro-
phages (Lassmann et al., 2007). Patients with MS may ben-
efit from TPE by removing autoantibodies, such as anti-
myelin antibody, or modulating immune response in acute
severe attacks of MS in patients who fail initial treatment
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Therapeutic plasma exchange (TPE) is used in many neurological disorders to remove immuno-
globulin and other immunologically active substances. We observed patients that were admitted
in Rîga East Clinical University Hospital “Gaiïezers”, Clinic of Neurology and Neurosurgery, Multi-
ple Sclerosis Unit, and were diagnosed with relapsing remitting multiple sclerosis (MS), according
to McDonald criteria 2010 (five patients), Neuromyelitis optica (NMO) spectrum disorders (three
patients) and one with NMO, according to Wingerchuk 2006 criteria. All relapses were confirmed
according to clinical criteria. Visual acuity was assessed by an ophthalmologist, and neurological
status by a neurologist. All patients received at least 1 cycle of 1000 mg methylprednisolone intra-
venous for five to seven days. The expanded disability status scale score in the MS patient group
was in range 4.0–9.0 before TPE and 3.5–6.5 range after TPE. Best improvement was observed
in the MS group: mean symptom reduction of 20%. Patients with NMO spectrum disorder had an
EDSS score of 8.0–8.5 range on admission and 6.5–8.0 range after TPE. After one month, one
patient in the NMO spectrum disorder group had good response to TPE and EDSS was 3.5, two
patients had only slight improvement (EDSS scores 8.0 and 7.5). Condition of patients with NMO
did not improve even after a month.
Key words: therapeutic plasma exchange, multiple sclerosis, neuromyelitis optica.
S h o r t C o m m u n i c a t i o n
269Proc. Latvian Acad. Sci., Section B, Vol. 69 (2015), No. 5.
with high-dose steroids. However, no major therapeutic ef-
fect of TPE can be expected once antibodies have been de-
posited in situ in CNS lesions (Weinshenker et al., 1999;
Szczepiorkowski et al., 2010).
Neuromyelitis optica is a severe idiopathic inflammatory
demyelinating disease that selectively affects optic nerves
and spinal cord, typically spares the brain, and generally
follows a relapsing course. In the majority of cases, patho-
genesis of NMO is associated with NMO–IgG, which binds
to aquaporin-4 (a water channel) on astrocyte foot processes
at the blood-brain barrier. Histopathology of NMO includes
deposition of IgG and complement in the perivascular space
with a granulocyte and eosinophil infiltrate, and hyalinisa-
tion of vascular walls (Lennon et al., 2004). Within five
years, 50% of patients lose functional vision in at least one
eye or are unable to walk independently. Early and accurate
diagnosis is important, since NMO carries a poorer progno-
sis than MS and the generally accepted treatment ap-
proaches differ (Wingerchuk et al., 2006). Approximately
80% of patients with NMO have a relapsing course, which
has a poor prognosis: 50% of patients become legally blind
or wheelchair bound and 30% die from respiratory failure
within five years. NMO worsens by incomplete recovery
with each acute attack. Acute attacks are managed by 1 cy-
cle of 1000 mg intravenous methylprednisolone for 5 to 7
days and, if this fails to resolve symptoms, TPE is added.
TPE removes the pathologic antibody, immune complexes,
and inflammatory mediators. Relapses are commonly resis-
tant to steroids, and TPE can be helpful in recovery from
acute attack, but does not prevent further relapses.
According to the existing recommendations, TPE is ap-
proved for use in NMO after a course of systemic steroids
and in case of MS only if initial therapy has no effect.
Present-day TPE is a continuous flow procedure where
elimination follows a linear passive process. For example, a
single exchange of 1 (approximately 3 l for a 70-kg patient),
1.5 and 2 plasma volumes removes 63%, 78%, and 86% of
all solutes in plasma, respectively.
Under normal circumstances, TPE removes 40–60 ml of
plasma/kg over 2–3 hours. Typically, blood components are
separated by either plasma filtration, which allows the re-
moval of all plasma components (i.e., except red blood
cells), or online centrifugation, which allows selective re-
moval of cell types depending on their respective specific
gravity (e.g., red blood cells or white blood cells). Replace-
ment fluids are dictated by the clinical scenario and they in-
clude colloids (e.g., 4–5% albumin), crystalloid/colloid
combination, or plasma (FFP, thawed plasma, or cryo-poor
plasma) (Ibrahim and Balogun, 2012).
The examined patients were admitted in the Rîga East Clini-
cal University Clinical Hospital “Gaiïezers”, Clinic of Neu-
rology and Neurosurgery, Multiple Sclerosis Unit, between
1 of January 2011 and 1 July 2014.
We recruited: five patients diagnosed with relapsing remit-
ting MS, according to McDonald criteria 2010, three pa-
tients with NMO spectrum disorders and one with NMO,
according to Wingerchuk criteria 2006. All patients had
more than one episode of relapse. Objective neurological
status and visual acuity were assessed before, on the second
day after the last TPE course and one month later. Disability
status was verified using the EDSS scale and muscle
strength was evaluated using the Medical Research Council
scale (MRC). All relapses were confirmed according to
clinical criteria. Relapse was clinically confirmed if the pa-
tient had any suspicion to optic neuritis and episode of neu-
rologic symptoms characteristic of the disease, without any
suspicion of infection, and that lasted for more than 24
hours.
Optic neuritis was confirmed by an ophthalmologist using
direct ophthalmoscopy. Patients with isolated myelitis or
optic neuritis were tested for aquaporin 4 (AQP 4) antibod-
ies in the blood using the Immunofluorescence/EIROIM-
MUN test.
All patients received at least 1 cycle of high dose intrave-
nous methylprednisolone 1000 mg for 5 to 7 days. TPE was
performed if visual acuity and neurological symptoms had
not recovered by 50% and the time after relapse onset was
3–8 weeks (mean 5.7 weeks).
Informed consent was obtained from all patients who were
included in the study. In most cases, patients were treated
with five cycles of TPE after placing a central venozus
catheter in a jugular- or subclavian vein. Approximately 2 l
of plasma were exchanged with 500.0 ml Haes and 1 l hu-
man albumin 5% using a Cobe spectra device with continu-
ous flow. Total blood and plasma volumes were calculated
by using standard equations. Blood tests and electrocardi-
ography (ECG) were made daily and after the last TPE pro-
cedure. TPE was given every other day for most of the pa-
tients.
Mean age in the MS group was 29.2 (19–38); mean age in
NMO group was 50 (43–63). The examined group consisted
of four men and five women. All patients from the NMO
group were treatment-naive, three patients from MS group
received IFN 1b s/c for 6 to 23 weeks (mean 13.3 weeks).
On admission all patients had severe neurological dysfunc-
tion: five patients had paraparesis, sensory deficit and urinal
retention, two patients had tetraparesis, two patients had pa-
resis in only one limb, and one patient had optic neuritis.
The expanded disability status scale (EDSS) had range from
4.0 to 9.0.
All patients received five TPE procedures, one in two days.
In the NMO spectrum disorders group, a slight change in
symptoms was seen only after the fifth TPE procedure and
was related with increase of muscle strength. In the relaps-
ing remitting MS patient group, the first changes in the neu-
rological status were observed after the second TPE proce-
dure, but two patients had changes in their neurological
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status only after the fifth TPE procedure. Unfortunately,
there was no benefit from TPE for one patient with NMO.
The expanded disability status scale score in the relapsing
remitting MS patient group was in the range 4.0–9.0 before
TPE and 3.5–6.5 after TPE. Patients 1 and 2 showed neuro-
logical symptom reduction by 20%, patients 3 and 5 had
symptom reduction by 13.34% and 12.5%, respectively, and
the best results were for patient 4 who showed symptom re-
duction by 36.36% after TPE. Patients with NMO spectrum
disorder had and EDSS score in the range 8–8.5 on admis-
sion and 6.5–8.0 range after TPE. The best result was for
patient 7 (symptom reduction by 18.75%); patients 6 and 8
had only a slight reduction in their symptoms (6% and
6.25%, respectively).
We evaluated symptoms one month after TPE. The effect
remained generally stable in the MS group, but patients 1
and 5 showed further symptom reduction: EDSS 5.5 and 3.0
after 1 month (improvement by 26.67% and 25% in com-
parison to results on admission).
The best response to TPE was by one patient in the NMO
spectrum disorder group, who had an EDSS score of 3.5 af-
ter 1 month (reduction by 56.25%). The other two patients
in the NMO spectrum disorder group showed no further im-
provement and their status remained stable 1 month after
TPE. Unfortunately, even after a month, one patient with
NMO had no improvement. (Summary of results is shown
in Table 1)
No serious adverse events occurred in our cohort. We ob-
served hypoproteinemia and in these cases TPE was inter-
rupted for aday.
Neurological diseases are the most common indications
treated by TPE (Kaya et al., 2013). European guidelines on
management of acute relapses of multiple sclerosis suggest
beneficial effect of TPE in cases when patients are refrac-
tory to treatment with high-dose methylprednisolone (Sel-
lebjerg et al., 2011). The American Academy of Neurology
guidelines recommend the use of TPE for adjunctive treat-
ment of exacerbations in relapsing forms of MS, and that
TPE can be considered in treatment of fulminant CNS de-
myelinating diseases that fail to respond to high-dose corti-
costeroid treatment (Cortese et al., 2011). The use of TPE in
NMO and NMO spectrum disorders is also recommended if
initial therapy with corticosteroids fails to improve any
symptoms (Sellner et al., 2010).
Basic TPE application is recommended at a rate of five
times daily or every other day; exchanging 1–1.5 times total
plasma volume per session, in patients with neurological
disease (Yilmaz et al., 2011; Kes et al., 2012). Five plasma
exchange sessions are usually prescribed and believed to be
sufficient to achieve antibody removal. The rate of extravas-

























1. I.V. 38 F MS Nystagmus, lower extremity paraparesis,
muscle strength dx 1, sin 2
7.5 4 Muscle strength dx
3, sin 4
6.0 5.5
2. L.Z. 25 F MS Nystagmus, dyplopia, asymmetric
tetraparesis, muscle strength dx 2, sin 3
7.5 5 Muscle strength dx
3, sin 4
6.0 6.0
3. L.F. 32 M MS Internuclear oftalmoplegy, tetraparesis,
muscle strength lower extremity 3
7.5 3 Muscle strength 4 6.5 6.5
4. L.A. 19 M MS Horizontal nystagmus, right leg paresis,
muscle strength 4
5.5 5 Muscle strength 5,
ataxia
3.5 3.5
5. A.S. 32 M MS Lowered visual fields, optic neuritis sin,
facial paresis dx, hemiparesis sin




6. L.S. 64 F NMO
spectrum
disorder
Lower extremity paraparesis, muscle
strength lower extremity 2, bowel dys-
function
8.5 5 Muscle strength dx
2, sin 4
8.0 8.0
7. K.P. 43 F NMO
spectrum
disorder
Lower extremity paraparesis, muscle
strength lower extremity 3, bowel dys-
function
8.0 5 Muscle strength dx
5, sin 3
6.5 3.5
8. D.R. 43 F NMO
spectrum
disorder
Lower extremity paraparesis, muscle
strength lower extremity 1-0, urinary dys-
function
8.0 5 Muscle strength 1 7.5 7.5
9. J.S. 30 M NMO Blindness, lower extremity paraparesis,
muscle strength lower extremity 1-0, uri-
nary dysfunction
9.0 5 No improvement 9.0 9.0
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cular to intravascular equilibration is approximately one to
two percent per hour, and five separate exchanges over
seven to ten days are required to remove 90% of the total
initial body immunoglobulin levels (Keller et al., 1978).
Predictors of good response to TPE include sex, age, type of
symptom, EDSS and the time of starting TPE after relapse
onset. Unfortunately, our study has some limitation: small
number of patients, delay in diagnostics, and fee for testing
AQP4.
There is some evidence from case series that TPE is effec-
tive for acute relapse treatment in NMO patients who do not
respond satisfactorily to high dose intravenous methyl-
prednisolone (Keegan et al., 2002; Watanabe et al., 2007;
Miyamoto et al., 2009; Yoshida et al., 2010). Moreover,
clinical response seems to be related to the early initiation
of treatment and it may be observed quickly once TPE ses-
sions are started (Watanabe et al., 2007).
Other case series that studied the effectiveness of TPE for
patients with MS and optic neuritis also showed benefit of
TPE for most patients (Weinshenker et al., 1999; Keegan et
al., 2002; Ruprecht et al., 2004). However, recommenda-
tions state that TPE should be approved for relapse remit-
ting MS patients (Cortese et al., 2011).
Our study is the first in Latvia that shows TPE effect on de-
myelinating diseases.
Unfortunately, due to lack of studies that included sub-
groups of patients with demyelinating diseases, it is not pos-
sible to determine if TPE is more or less effective in pa-
tients with different demyelinating diseases. Analysis of
studies showed that NMO relapse is best resolved by treat-
ment with intravenous methylprednisolone, followed by a
TPE course, and that EDSS should be evaluated at 1, 6 and
12 months.
There are many studies that showed changes of AQP4 and
oligoclonal bands titre after TPE (Yoshida et al., 2010; Mu-
nemoto et al., 2011), which was not analysed in the present
study as the oligoclonal band test was not made for all pa-
tients.
In the future, to improve practical and scientific use of TPE
in cases of demyelinating diseases, we recommend to meas-
ure AQP4 level at 6 and 12 months and to evaluate EDSS
more often than in the present study.
There are a number of side effects of TPE — hypotension,
hypocalcaemia, infection, embolism, bleeding. We did not
observe any side effects mainly due to the small number of
patients.
TPE is a safe and efficient add-on therapy in CNS demyeli-
nating diseases.
Further prospective research is necessary to establish the
role of TPE. Our study is limited by lack of a control group
and the low number of patients, and more patients are
needed for further studies. It would be a great advantage to
estimate AQP4 and OCB titres after TPE.
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IMÛNMODULÇJOÐÂS TERAPIJAS EFEKTIVITÂTE CENTRÂLÂS NERVU SISTÇMAS IEKAISÎGU SASLIMÐANU GADÎJUMOS:
DEVIÒU PACIENTU ANALÎZE
Terapeitiska plazmas apmaiòa (TPA) tiek lietota noteiktu neiroloìisku saslimðanu gadîjumos ar mçríi no organisma izvadît imûnglobulînus
un citas imunoloìiski aktîvas substances. Pçtîjumâ tika ietverti un izvçrtçti pacienti, kas ârstçjâs Rîgas Austrumu klîniskajâ universitâtes
slimnîcâ “Gaiïezers” Neiroloìijas un neiroíirurìijas klînikâ, multiplâs sklerozes vienîbâ ar diagnozçm: multiplo sklerozi (MS), recivçjoði
remitçjoðu norisi (balstoties uz 2010. gadâ izstrâdâtajiem McDonald kritçrijiem (pieci pacienti)), optiskâ neiromielîta spektra saslimðanu
(trîs pacienti) un optisku neiromielîtu (viens pacients). Visi slimîbas saasinâjumi tika apstiprinâti, balstoties uz atbilstoðiem klîniskajiem
kritçrijiem. Pacientu redzes traucçjumus izvçrtçja oftalmologs, savukârt neiroloìisko stâvokli — neirologs. Visi pacienti terapijas ietvaros
5–7 dienas saòçma metilprednizonu 1000 mg intravenozi sistçmu veidâ. Invaliditâtes izvçrtçðanas skalas (IIS) punktu skaits MS grupâ bija
4,0–9,0 un 3,5–6,5 pçc TPA. Pacientiem ar optiskâ neiromielîta spektra slimîbu IIS punktu skaits bija 8,0–8,5 diapazonâ stacionçðanas laikâ
un 6,5–8,0 diapazonâ pçc TPA. Vienam pacientam ar NMO spektra slimîbu bija labs rezultâts pçc TPA, IIS punktu skaits bija 3,5, bet
pârçjiem diviem bija tikai minimâls uzlabojums lîdz 7,5. Optiska neiromielîta pacientam pçc TPA, izvçrtçjot klîniskos simptomus
saasinâjuma sâkumâ un pçc 1 mçneða, uzlabojumu nenovçroja.
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